LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Ouvert

SecteurSoins de santé

1.9

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.87

Max

1.98

Chiffres clés
By Trading Economics
Revenu	-3.8M -43M
BPA	-0.18
Employés	150
EBITDA	-3.9M -43M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+348.97% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-117M 670M
Ouverture précédente	1.9
Clôture précédente	1.9

Sentiment de l'Actualité

By Acuity

50%

174 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.18 / 1.69 Support & Résistance

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 mai 2026, 20:36 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Résultats

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Résultats

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mai 2026, 22:02 UTC

Résultats

ZTO Express (Cayman): Di Xu to Resign From Board

19 mai 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mai 2026, 22:01 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mai 2026, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mai 2026, 21:37 UTC

Résultats

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mai 2026, 21:01 UTC

Résultats

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mai 2026, 20:58 UTC

Résultats

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mai 2026, 20:46 UTC

Actions en Tendance

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mai 2026, 20:34 UTC

Résultats

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries 4Q EPS 5c >JHX

19 mai 2026, 20:32 UTC

Résultats

James Hardie Industries 4Q Sales $1.4B >JHX

19 mai 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mai 2026, 20:03 UTC

Acquisitions, Fusions, Rachats

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mai 2026, 20:03 UTC

Acquisitions, Fusions, Rachats

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mai 2026, 20:02 UTC

Acquisitions, Fusions, Rachats

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mai 2026, 20:02 UTC

Acquisitions, Fusions, Rachats

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

348.97% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 348.97%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.18 / 1.69Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

174 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.